Seeking Alpha

Celgene (CELG -4.3%) gets FDA approval for its supplemental new drug application for Revlimid to...

Celgene (CELG -4.3%) gets FDA approval for its supplemental new drug application for Revlimid to treat mantle cell lymphoma. The drug is already cleared for multiple myeloma, another white blood cell cancer. Analysts estimate the drug could generate around $5.9B in sales in 2016.
Comments (3)
  • What's up with the Biotech's? CELG and GILD got hammered again.. has the whole market turned here and this is the time to bail?
    5 Jun 2013, 04:18 PM Reply Like
  • good question, esp after they get FDA approval and still don't rally!
    5 Jun 2013, 06:16 PM Reply Like
  • Now, even with the FDA Approval and positive futures, the stock is bare moving ... is this a pure sector rotation or just the beginning of the 10 - 15% sell off?
    6 Jun 2013, 09:11 AM Reply Like
DJIA (DIA) S&P 500 (SPY)